Could the future of PrEP be just two injections per year? Help us find out.

Even though a variety of prevention options exist, HIV remains a serious health concern for many people around the world. PURPOSE 2 will test whether an investigational PrEP (pre-exposure prophylaxis) medicine, lenacapavir, helps reduce the chance of getting HIV through sex.

Answer a few quick questions below to determine if you’re eligible to participate in the study. If eligible, we’ll contact you to schedule a screening visit at our Hamden health center.

Participants may receive up to $150 for a screening visit, which includes a free rapid HIV test, and up to $2,250 for their time in the study if they qualify.

For more information, please call 203-903-8308, email clinicaltrials@ahicorp.org, or visit PURPOSE 2’s website page.

clinicaltrials.gov identifier: NCT04925752